Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1208/s12249-014-0143-6 http://scihub22266oqcxt.onion/10.1208/s12249-014-0143-6 C4179653!4179653 !24927668     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24927668 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       AAPS+PharmSciTech 2014 ; 15 (5 ): 1345-54 Nephropedia Template TP {{tp|p=24927668 |t=2014. Nanoparticle ligand presentation for targeting solid tumors |pdf=|usr=}}{{24927668 }} gab.com Text Nanoparticle ligand presentation for targeting solid tumors JO: AAPS PharmSciTech http://www.kidney.de/pget.php?&tw=1&pmid=24927668 #FOAvip Among the many scientific advances to come from the study of nanoscience, the development of ligand-targeted nanoparticles to eliminate solid tumors is predicted to have a major impact on human health. There are many reports describing novel designs and testing of targeted nanoparticles to treat cancer. While the principles of the technology are well demonstrated in controlled lab experiments, there are still many hurdles to overcome for the science to mature into truly efficacious targeted nanoparticles that join the arsenal of agents currently used to treat cancer in humans. One of these hurdles is overcoming unwanted biodistribution to the liver while maximizing delivery to the tumor. This almost certainly requires advances in both nanoparticle stealth technology and targeting. Currently, it continues to be a challenge to control the loading of ligands onto polyethylene glycol (PEG) to achieve maximal targeting. Nanoparticle cellular uptake and subcellular targeting of genes and siRNA also remain a challenge. This review examines the types of ligands that have been most often used to target nanoparticles to solid tumors. As the science matures over the coming decade, careful control over ligand presentation on nanoparticles of precise size, shape, and charge will likely play a major role in achieving success. Twit Text FOAVip Nanoparticle ligand presentation for targeting solid tumors ????AAPS PharmSciTech http://www.kidney.de/pget.php?&tw=1&pmid=24927668 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24927668 #FOAvip English Wikipedia <ref>{{Cite pmid|24927668 }}</ref> Nanoparticle ligand presentation for targeting solid tumors #MMPMID24927668 Duskey JT ; Rice KG AAPS PharmSciTech 2014[Oct]; 15 (5 ): 1345-54 PMID24927668 show ga Among the many scientific advances to come from the study of nanoscience, the development of ligand-targeted nanoparticles to eliminate solid tumors is predicted to have a major impact on human health. There are many reports describing novel designs and testing of targeted nanoparticles to treat cancer. While the principles of the technology are well demonstrated in controlled lab experiments, there are still many hurdles to overcome for the science to mature into truly efficacious targeted nanoparticles that join the arsenal of agents currently used to treat cancer in humans. One of these hurdles is overcoming unwanted biodistribution to the liver while maximizing delivery to the tumor. This almost certainly requires advances in both nanoparticle stealth technology and targeting. Currently, it continues to be a challenge to control the loading of ligands onto polyethylene glycol (PEG) to achieve maximal targeting. Nanoparticle cellular uptake and subcellular targeting of genes and siRNA also remain a challenge. This review examines the types of ligands that have been most often used to target nanoparticles to solid tumors. As the science matures over the coming decade, careful control over ligand presentation on nanoparticles of precise size, shape, and charge will likely play a major role in achieving success. |*Nanoparticles [MESH] |Animals [MESH] |Antineoplastic Agents/administration & dosage/*therapeutic use [MESH] |Chemistry, Pharmaceutical [MESH] |Drug Delivery Systems/*methods [MESH] |Humans [MESH] |Ligands [MESH] |Nanomedicine [MESH]Nanoparticle ligand presentation for targeting solid tumors (epmc).pdf DeepDyve Pubget Overpricing